Trial Profile
Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment (PCV)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
- 30 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.